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carcinomaAbstract There is increased need for classiﬁcation of non-small cell lung cancer (NSCLC) into its
major subtypes, adenocarcinoma (AC) and squamous cell carcinoma (SCC). Such a classiﬁcation is
enabled in poorly differentiated tumours based on routine morphology due to overlapping morpho-
logic features. In such cases, the use of immunohistochemistry (IHC) can differentiate between the
two subtypes.
Purpose: To test the ability of the two markers; Napsin-A and Desmocollin-3, in differentiating
poorly differentiated (AC) from poorly differentiated SCC in small biopsies.
Patients and methods: This is a retrospective study including 60 patients who presented with pul-
monary nodules. Cases with biopsy specimens diagnosed as poorly differentiated non-small cell
lung cancer, and had corresponding resection specimens were included. Cell blocks were stained
with anti Napsin-A, and anti Desmocollin-3. Cytoplasmic immunoreactivity for both markers
was considered speciﬁc. Sensitivity, speciﬁcity, positive and negative predictive values, total accu-
racy and combined accuracy of both markers were calculated.
Results: Napsin A showed a sensitivity of 89.3%, a speciﬁcity of 96.9%, PPV of 96.2%, NPV of
91.2%, and a total accuracy of 93.3% for AC, while Desmocollin-3 achieved 90.6% sensitivity,
96.4% speciﬁcity, 96.7% PPV, 90% NPV, and 93.3% total accuracy. Both markers achieved a total
accuracy of 90%.
Conclusion: Napsin-A, and Desmocollin-3 were sensitive and speciﬁc markers for the diagnosis of
AC and SCC, respectively. Both markers allowed classiﬁcation of 54/60 cases into either AC or
SCC.
 2015 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Lung cancer is considered the most common cause of cancer-
related mortality in the world. Nowadays; people die of lung
14 N.E.-S. Ezzat, N. Tahouncancer more than of breast, colon, and prostate cancers com-
bined [1].
Lung cancer has been classiﬁed into two clinically impor-
tant groups: small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC). NSCLC represents 75–85% of lung
cancer, and consists of several types, of which adenocarcinoma
(AC) is the most frequent subtype [2]. On the other hand, small
cell lung cancer accounts for 15–25% of cases, it has neuroen-
docrine features, and is treated with chemotherapy and/or
radiotherapy. The distinction was clinically important as the
treatment lines are totally different between the two groups [3].
Recently, the simple distinction of lung cancer into SCLC
and NSCLC is no longer acceptable. Some chemotherapeutic
drugs were found to be more effective in SCC, whereas others
were more active in the non-squamous type. Hence there is an
increased need for classiﬁcation of NSCLC into its major sub-
types in preoperative and surgical specimens. In addition, a
difference in response to target therapies was found between
speciﬁc subtypes of NSCLC [4].
Moreover, there were some drugs that are contraindicated
in SCC due to the risk of pulmonary hemorrhage e.g. beva-
cizumab (Avastin), and pemetrexed (Alimta), which necessi-
tates accurate distinction between the two sub-types [5].
The current WHO classiﬁcation of lung cancer has been
based on assessment of morphologic criteria using hema-
toxylin and eosin (H&E) stained slides. However, this distinc-
tion is not always possible in poorly differentiated tumors, due
to overlapping morphologic features, especially in small biop-
sies and cytologic material that is used in the diagnostic
workup, in such cases focal evidence of differentiation is
difﬁcult due to amount of material, scant cellularity, crushing
artifact, and cell dispersal. In these cases the diagnosis of
(NSCLC) is used as a general approach in a variable percent-
age of these specimens [6].
As 70% of NSCLC cases are present at an un-resectable
stage, the only diagnostic measure guiding the therapy in the
majority of patients is a small specimen. In such cases the
use of immunohistochemistry (IHC) can differentiate AC from
SCC. Recent studies revealed that IHC can increase the accu-
racy and reproducibility, and decreases the number of non-
small cell carcinoma—not otherwise speciﬁed (NSCLC-NOS)
diagnoses in small specimens from 30–40% to 4–7% [7,8].
Several recent studies have demonstrated that the use of
immunohistochemical (IHC) markers can be helpful in deﬁn-
ing a speciﬁc cell lineage, especially differentiating (SCC) from
(AC)—not on surgical material only, but on small biopsy sam-
ples and cytology also [9].
It has been shown in the literature that the application of a
simple panel of IHC markers using the newly described anti-
bodies Desmocollin-3 and Napsin can subtype NSCLC with
a high degree of diagnostic accuracy [10,11].
Napsin-A is an aspartic proteinase, belonging to the pepti-
dase A1 family, it is present abundantly in certain cells, such as
type II pneumocytes, alveolar macrophages, renal tubular cells
and in lung adenocarcinomas as well as renal cell carcinomas.
In the lung, it plays a role in the regulation of maturation and
activation of surfactant protein B [12].
In the literature, the sensitivity of Napsin-A for lung adeno-
carcinoma ranged from 58% to 90%, and speciﬁcity from
90.7% to 100% [7,13–19].
Descmocollin-3 (DSC3) is a member of cadherin superfam-
ily of calcium-dependent cell-adhesion molecules, The anti-desmocollin 3 antibody localizes Desmocollin 3 in the epider-
mal layers, glandular ductal cells, basal matrix cells, basal
and supra basal layers of stratiﬁed epithelia, and thymic retic-
ulum cells [20].
In lung cancer, the diagnostic value of DSC3 in squamous
carcinoma has been reported. Recent studies have indicated
that the sensitivity of DSC3 for diagnosing pulmonary SCC
has ranged from 52% to 100% and the speciﬁcity reached
up to 100% [11,18,21].
In the current study we investigate the utility of the two new
markers, Napsin A and Desmocollin-3, in differentiating
between poorly differentiated pulmonary AC and SCC in
small biopsy samples, which will be conducted on a group of
Egyptian patients, and compare our results to those published
in previous studies.Patients and methods
Our retrospective study was conducted on 60 patients who pre-
sented with primary pulmonary nodules. Parafﬁn blocks were
collected from the Pathology department, National Cancer
institute, Cairo University, in the period from January 2013
to March 2015. Patients’ data were reviewed and information
about age and sex of the patient, size and site of pulmonary
nodules, and any relevant radiological and clinical data was
recorded.
Cases with a biopsy diagnosed as poorly differentiated non-
small cell lung cancer, and having a corresponding resection
specimen were included in the study. Biopsy was done either
by transthoracic core biopsy, or bronchoscopic biopsy.
Surgical procedure included lobectomy, wedge resection, seg-
mentectomy, and orpneumonectomy. All hematoxylin and
eosin slides of formalin-ﬁxed, parafﬁn embedded tumor tissue
were reviewed to conﬁrm the histologic diagnosis according to
the current World Health Organization (WHO) classiﬁcation
[8], and to select the best area for immunostaining. Biopsy
specimens showing insufﬁcient cellularity or bad quality were
considered inadequate and excluded from the study.
The resection specimens were diagnosed as AC or SCC,
where areas of differentiation into either histologic type were
present. Adenocarcinoma was characterized by the presence
of glandular formations, and/or intracellular mucin, while
squamous differentiation was characterized by intracellular
or extracellular keratin, and the presence of intercellular
bridges.
From the block of every biopsy, 2 sections of 5 lm thick-
ness were prepared on electrostatically charged glass slides
and subjected to immunostaining according to the avidin–
biotin complex (ABC) immunoperoxidase method using
Napsin-A, (the rabbit polyclonal antibody from the manufac-
turer Cell Marque, clone; 452A-7x, ready to use), for AC, and
Desmocollin-3, (mouse monoclonal antibody from the manu-
facturer Biorbyt, clone Dsc3-U114, ready to use), for SCC.
The reaction was detected using Diaminobenzidine (DAB),
and the slides were counterstained with hematoxylin, and
examined for both markers expression. Only the cytoplasmic
immunoreactivity for Napsin-A, and desmocollin-3 was con-
sidered speciﬁc. Slides were reported as positive if >10% of
the neoplastic cells showed cytoplasmic staining [9]. Appropri-
ate positive control (Pneumocytes were considered internal
positive control for Napsin-A, and basal bronchial cells for
Napsin A and Desmocollin-3 IHC in poorly differentiated NSCLC 15Desmocollin-3) and negative control (by substituting Phos-
phate Buffer Saline (PBS) for the primary antibody) were used
to evaluate the quality of the procedure of staining and the
amount of non-speciﬁc reaction that is not referred to binding
of the antibody of interest speciﬁcally to its targeted antigen.
The immunostaining was scored as follows: score 0, no
reactivity; score 1, weak intensity: less than normal cells; score
2, moderate intensity: the same as normal cells; and score 3,
strong intensity: more than normal cells [18].
Sensitivity, speciﬁcity, positive and negative predictive val-
ues, and total accuracy for each marker and combined accu-
racy of both markers were calculated by comparing results
of immunostaining of biopsy with the resection specimens.
Results
The present study included 60 patients who presented with
solitary lung lesions. The age of the patients ranged from 47
to 79 with a median of 46, and a mean of 64.13. Sixteen
patients were females representing 26.7% of patients, while
44 were males representing 73.3% of patients. The female to
male ratio was 1:2.75. The right lung showed 63.3% of lesions,
while the remaining 36.7% of lesions was located in the left
lung. Twenty percent of lung masses was <2 cm, 65% of
masses ranged between 2 and 5 cm, while 15% was >5 cm
(Table 1).
By comparing the biopsy of the 60 cases of poorly differen-
tiated carcinoma with the resection specimens, it was found
that 28 (46.7%) cases were classiﬁed as poorly differentiated
adenocarcinoma (Figs. 1 and 3), and 32 (53.3%) as poorly dif-
ferentiated squamous cell carcinoma (Figs. 2, 4 and Table 2).
When IHC was applied it was found that Napsin A showed
positive cytoplasmic immunostaining in 25/28 (89.3%) of AC
cases (Fig. 5), and negative staining in 3 (10.7%) cases,
(Fig. 7). On the other hand, Desmocollin-3 stained 29/32
(90.6%) of SCC (Fig. 8), while 3(9.4%) cases were negative
(Fig. 10 and Table 3)
Thus Napsin A showed a sensitivity of 89.3%, a speciﬁcity
of 96.9%, PPV of 96.2%, NPV of 91.2%, and a total accuracy
of 93.3% for AC, while Desmocollin-3 achieved 90.6%Table 1 Clinico-radiological data.
Clinico-radiologic parameter NO %
Age
40–50 3 5
51–60 21 35
61–70 19 32
71–80 17 28
Sex
Females 16 26.7
Males 44 73.3
Site
Rt 38 63.3
Lt 22 36.7
Size
<2 cm 12 20
2–5 cm 39 65
>5 cm 9 15sensitivity, 96.4% speciﬁcity, 96.7% PPV, 90% NPV, and
93.3% total accuracy.
When results of the 2 markers were combined, double pos-
itive, double negative, and cases with reverse staining pattern
were excluded. It was found that both markers achieved a
combined total accuracy of 90%, thus 54/60 cases could be
accurately classiﬁed as either adenocarcinoma, or squamous
cell carcinoma, and only 6 (10%) cases remained unclassiﬁed,
later proved to be [AC 3 cases (50%), and SCC 3 cases (50%)].
Regarding the scoring of the immunostaining, it was found
that Napsin A showed a score 1 immunostaining in 2 (8%)
cases (Fig. 6), score 2 in 15 (60%) cases, and score 3 in 8
(32%) cases (Fig. 5). In the case of Desmocollin-3,4 (13.8%)
cases were scored as score 1 (Fig. 9), 18 (62.1%) cases as score
2, and 7 (24.1%) cases as score 3 (Fig. 8 and Table 4).Discussion
Differentiating SCC from AC has become clinically important
for tailoring the appropriate systemic treatment, identifying
patients for targeted therapies and for genetic evaluation [5].
Although the reproducibility rate for the diagnosis of glan-
dular vs. squamous differentiation in well to moderately differ-
entiated AC and SCC, based on routine microscopic features is
satisfactory, it is less than satisfactory for discriminating
(poorly differentiated) PD SCC from PD AC, especially in
small biopsy material due to several factors, such as crush arti-
fact, the presence of necrosis, less than optimal ﬁxation, and
the overlapping cytologic features. Accordingly, about 75%
of NSCLCs need only routine H&E staining to be diagnosed
as AC or SCC in biopsy specimens [22,23].
The usefulness of the application of multiple markers for
differentiating PD AC from PD SCC is well established but
some previous studies recommended the minimal number of
markers needed for reliably subtyping PD NSCLC [7,17,23].
The 2011 guidelines of the International Association for the
Study of Lung Cancer (IASLC)/American Thoracic Society
(ATS)/European Respiratory Society (ERS) for classiﬁcation
of lung AC recommended the reduction of immunohistochem-
ical markers applied to small biopsies (one SCC marker and
one AC marker), in order to preserve as much of the specimens
for molecular testing [24].
Several novel antibodies were introduced for differentiating
pulmonary AC and SCC. Napsin A, an aspartic proteinase
involved in the maturation of surfactant protein B, has been
recommended as a new diagnostic marker for pulmonary AC
[12].
Recently, Desmocollin-3, a protein found in desmosomes,
has been proved to identify squamous differentiation, its
expression was detected in 100% of pulmonary SCCs [11].
This study was limited to surgically resected cases to pro-
vide an accurate comparison with the ﬁnal tumor subtyping.
Napsin A was an acceptable predictor for pulmonary adeno-
carcinoma, its reactivity was detected in 25/28 of AC, reﬂected
in a sensitivity of 89.3%, in agreement with a previously pub-
lished report, Ao et al. showed a sensitivity of 89.6% [19]. On
the other hand our ﬁgure was higher than that achieved by
other studies where they showed a sensitivity ranging between
38% and 87% [7,13,14,16–18,25,26]. Reasons for discrepancies
between our results and others could be attributed to differ-
ences in a number of cases, using different clones of antibodies,
Figure 1 Tissue biopsy from a case of poorly differentiated carcinoma, proved to be adenocarcinoma showing groups of malignant
epithelial cells with a marked degree of anaplasia (H&E 200).
Figure 2 Core biopsy from a case of poorly differentiated carcinoma conﬁrmed as Squamous cell carcinoma, showing a group of
malignant cells exhibiting marked anaplasia (H&E 200).
16 N.E.-S. Ezzat, N. Tahounand different methods of staining. In addition, the whole tissue
section was not used in the present study, thus the detailed
marker expression was enabled.
On the other hand, 1/32 cases of SCC showed focally positive
cytoplasmic staining forNapsinA, thus the speciﬁcity ofNapsinA in the present study was 97%, our results were nearly similar
to those reported by other authors as they achieved a speciﬁcity
of 98%, 99%, and 100% [16,14,7,18,13,28,17,25,26], while our
results were higher than Ao et al., where they showed a speci-
ﬁcity of 90% [19]. The reason for such lower speciﬁcity could
Figure 3 Tissue biopsy from a case of poorly differentiated carcinoma showing groups of malignant cells having marked anaplasia,
proved as adenocarcinoma (H&E 400).
Figure 4 Core biopsy of a poorly differentiated case showing groups of malignant epithelial cells exhibiting marked anaplasia, and
proved to be squamous cell carcinoma (H&E 200).
Napsin A and Desmocollin-3 IHC in poorly differentiated NSCLC 17be due to using a lower speciﬁcity clone of Napsin A, while the
higher speciﬁcity clones are either non-reactive or showing only
focal or weak reactivity.
In the current work the PPV and NPV achieved by Napsin
A were 96.2% and 91.2%, respectively, when our results were
compared with Kim et al. [16], it was found that they showed anearly similar PPV of 97%, and a lower NPV of 89%, while
Turner et al. [25], reported a higher PPV of 98%, and a lower
NPV of 83.
The disagreement between our and their results could be
due to the difference in the sample size, and using a small sized
biopsy having a limited number of cells available for
Table 2 Comparison between biopsy and resection specimens.
Biopsy Total no. Resection specimen
AC SCC
Poorly diﬀerentiated
carcinoma
60 28(46.7%) 32(53.3%)
18 N.E.-S. Ezzat, N. Tahouninterpretation. Also different clones of Napsin A could cross
react with cells other than targeted tumor cells; Ikeda et al.
reported that in addition to tumor cells, Napsin A showed
strong reactivity with histiocytes, leading to confusion in
results [27].
Focusing on the importance of different clones of Napsin
A, Mukhopadhyay and Luise have tested two clones of Napsin
A, one is the mouse monoclonal antibody and the other is the
rabbit polyclonal one, in order to determine lung origin in
metastatic adenocarcinomas. They reported that monoclonal
Napsin A is less sensitive than TTF-1 for metastatic adenocar-
cinomas of the lung (76% vs 82%). The sensitivity of Napsin A
increased minimally to 81% when polyclonal antibody was
used, but this increase is associated with a signiﬁcant decrease
in the speciﬁcity [28].
In the current study, Desmocollin-3 positively stained 29/32
cases of SCC, giving a sensitivity of 90.6%, our results agreed
with those detected by Kim et al. where they achieved 91%
sensitivity [16]. On the other hand, our ﬁndings were lower
than those detected by Monica et al. (100%) [11], and Warth
et al. (99%) [29], while our ﬁgures were higher than those
observed by Tsuta et al. where they showed a sensitivity of
72.7% for all SCC cases, and 52.2% for poorly differentiated
cases included in the study [21], and Righi et al. who achieved a
sensitivity of 81.5% [26].Figure 5 Core biopsy from a case of adenocarcinoma showing po
immunostain 200).This discrepancy in results could be due to using different
antibodies, and technologies. In addition, staining evaluation
and interpretation may show a wide range of variability
between different pathologists. Moreover, since Desmocollin
is a cytoplasmic marker, it can be subjected to non-speciﬁc
reactivity and difﬁculty in interpretation as it can occur with
other cytoplasmic markers [30].
In a recent study done by Zahn and colleagues, a number of
genes identiﬁed as immunohistochemical markers distinguish-
ing lung AC from lung SCC were tested. These genes include
MLPH, TMC5, SFTA3, DSG3, DSC3 and CALML3. Desmo-
collin 3 was reported to be one of the most sensitive and speci-
ﬁc markers in differentiating lung AC from lung SCC, giving
sensitivity and speciﬁcity of 90% and 97%, respectively [31].
Cui and his colleagues analyzed the expression of DSC1–3
mRNAs by RT-PCR. They used demethylation tests and bisul-
ﬁte sequencing to analyze the methylation status. Protein
expression of DSCs in primary lung cancer was evaluated by
IHC on tissue microarrays. They noticed that DSC1–3
mRNAs were down regulated in lung cancer cells. In a study
that included 199 patients with a history of primary lung can-
cer, they found that DSC3 proteins were more expressed in
SCC compared with ADC (p< 0.001), and that reduced
expression of DSC3 was correlated with poor clinical outcome
[32].
The previously mentioned studies lightened the signiﬁcant
role of Desmocollin 3 in the pathogenesis of lung cancer,
and its importance as a diagnostic and prognostic marker.
Although 1/28 cases of AC were reactive for Desmocollin-
3, such reactivity was either relatively weak or focal. Our ﬁnd-
ings regarding Desmocollin-3 speciﬁcity (96.4%) was slightly
lower than that reported in other studies, where they achieved
a speciﬁcity of 100%, each [11,16,21,26,29].sitive and strong cytoplasmic staining for Napsin A (Napsin-A
Figure 6 Tissue biopsy from a case of adenocarcinoma showing faint cytoplasmic staining for Napsin-A (stronger staining for internal
positive control) (Napsin-A immunostain 200).
Figure 7 Tissue biopsy from a case of adenocarcinoma showing negative cytoplasmic staining for Napsin-A, (internal positive control)
(Napsin-A immunostain 200).
Napsin A and Desmocollin-3 IHC in poorly differentiated NSCLC 19Our Desmocollin PPV, and NPV were 96.7% and 90%,
respectively, in the study done by Kim et al., the PPV and
NPV were 100%, and 88%, respectively [16].
The two markers used in the present study could accurately
classify 90% of the poorly differentiated cases as either AC or
SCC. The remaining 10% of cases were interpreted as eitherdouble positive or double negative, in such a case, application
of additional markers such as TTF-1 for AC, and P63 for SCC
can solve the problem. To our knowledge there were no previ-
ous reports in the literature examining the combined accuracy
of both Napsin A and Desmocollin-3 in classifying poorly dif-
ferentiated NSCLC to either subtype. Niclson et al. proposed a
Figure 8 Tissue biopsy from a case of squamous cell carcinoma showing positive and strong cytoplasmic and membranous reactivity for
Desmocollin-3 (Desmocollin-3 immunostain 400).
Figure 9 Tissue biopsy showing faint positive cytoplasmic staining for Desmocollin-3 in a case of squamous cell carcinoma
(Desmocollin-3 immunostain 400).
20 N.E.-S. Ezzat, N. Tahounpanel of CK5/6, p63, TTF-1 and d-PAS stain during small
biopsy sample evaluation [33]. Diagnostic reﬁnement was
enabled in 65% of tested questionable cases to either ADC
or SCC. The study included CK5/6, HMWCK, p63, TTF-1
and d-PAS and did not include desmocllin-3 and Napsin A
in contrast to our study. Loo and colleagues successfully sub-typed undifferentiated NSCLC in bronchial biopsy specimens
using a mucin stain plus p63 and TTF-1 [23]. This panel
reduced the proportion of specimens labeled as NSCLC-
NOS without deﬁnitive or probable histologic subtype to
7%. Mukhopadhyay and Katzenstein further reported that a
combination of CK5/6, Napsin A, p63, and TTF-1 markers
Figure 10 Biopsy specimen from a case of squamous cell carcinoma showing negative cytoplasmic staining (Desmocollin-3 immunostain
400).
Table 3 Immunostaining of Napsin A and Desmocollin-3.
Diagnosis Napsin A Desmocollin-3
+  + 
Adenocarcinoa 25(89.3%) 3(10.7%) 1(3.6%) 27(96.4%)
Squamous cell carcinoma 1(3.1%) 31(96.9%) 29(90.6%) 3(9.4%)
Table 4 Scoring of immunostaining.
Marker Total no of cases Score 0
(negative)
Score 1
(faint)
Score 2
(moderate)
Score 3
(strong)
Napsin A 28 3(10.7%) 2(7.1%) 15(53.6%) 8(28.6%)
Desmocollin-3 32 3(9.3%) 4(12.5%) 18(56.3%) 7(21.9%)
Napsin A and Desmocollin-3 IHC in poorly differentiated NSCLC 21allowed accurate classiﬁcation in 77% of PD NSCLCs [7].
Noh and Shim [17] examined the expression of 6 markers
(CK5/6, CK7, Napsin A, p63, SOX2, and TTF-1) and identi-
ﬁed the panel of Napsin A, p63 and TTF-1.
From our study we concluded that both Napsin-A, and
Desmocollin-3 were sensitive and speciﬁc markers for the diag-
nosis of AC and SCC, respectively. The combined markers
were able to address the correct tumor histotype in 90% of
poorly differentiated cases into either adenocarcinoma or
squamous cell carcinoma in small biopsies, and were helpful
to reduce the percentage of unclassiﬁed lung biopsies, suggest-
ing the most probable histotype of tumors, thus deﬁning a role
for immunoproﬁling in NSCLC to support histology-based
selection of systemic therapy.Conﬂict of interest
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